The use of a bioactive skin substitute decreases length of stay for pediatric burn patients
- PMID: 11479839
- DOI: 10.1053/jpsu.2001.25678
The use of a bioactive skin substitute decreases length of stay for pediatric burn patients
Abstract
Background: To optimize burn care for children, the authors introduced a protocol incorporating the use of a bioactive skin substitute, TransCyte (Advanced Tissue Sciences, La Jolla, CA). This study was designed to determine whether this management plan was safe, efficacious, and decreased hospital inpatient length of stay (LOS) compared with conventional burn management in children.
Methods: All pediatric burns greater than 7% total body surface area (TBSA) that occurred after October 1999 underwent wound closure with TransCyte (n = 20). These cases were compared with the previous 20 consecutive burn cases greater than 7% TBSA that received standard therapy. Standard therapy consisted of application of antimicrobial ointments and hydrodebridement. The following information was obtained: burn mechanism, age, size of burn, requirement of autograft, and LOS. Data were analyzed using the student's t test.
Results: Data for age, percent TBSA burn and LOS are reported as means +/- SEM. The children who received standard therapy were 2.99 +/- 0.7 years compared with those receiving TransCyte were 3.1 +/- 0.8 years. There was no difference between the treatment groups with regard to percent TBSA burn: standard therapy, 14.3 +/- 1.4% TBSA versus TransCyte, 12.7 +/- 1.3% TBSA. There was no difference in the type of burns in each group, the majority were liquid scald type, 70% in the standard therapy group versus 90% in the TransCyte group. Only 1 child in the TransCyte group required autografting (5%) compared with 7 children in the standard therapy group (35%). Children treated with TransCyte had a statistically 6 significant decreaed LOS compared with those receiving standard therapy, 5.9 +/- 0.9 days versus 13.8 +/- 2.2 days, respectively (P =.002).
Conclusions: This is the first study using TransCyte in children. The authors found that this protocol of burn care was safe, effective, and significantly reduced the LOS. This new approach to pediatric burn care is effective and improves the quality of care for children with burns.
Copyright 2001 by W.B. Saunders Company.
Similar articles
-
Use of Transcyte and dermabrasion to treat burns reduces length of stay in burns of all size and etiology.Burns. 2006 Nov;32(7):828-32. doi: 10.1016/j.burns.2006.04.003. Epub 2006 Sep 25. Burns. 2006. PMID: 16997480
-
Should dermal scald burns in children be covered with autologous skin grafts or with allogeneic cultivated keratinocytes?--"The Viennese concept".Burns. 2005 Aug;31(5):578-86. doi: 10.1016/j.burns.2005.01.001. Epub 2005 Feb 19. Burns. 2005. PMID: 15993303
-
Treatment of partial-thickness burns: a prospective, randomized trial using Transcyte.ANZ J Surg. 2004 Aug;74(8):622-6. doi: 10.1111/j.1445-1433.2004.03106.x. ANZ J Surg. 2004. PMID: 15315558 Clinical Trial.
-
Burn wound healing and skin substitutes.Burns. 2001 Aug;27(5):517-22. Burns. 2001. PMID: 11451610 Review.
-
Preliminary results in single-step wound closure procedure of full-thickness facial burns in children by using the collagen-elastin matrix and review of pediatric facial burns.Burns. 2015 Sep;41(6):1268-74. doi: 10.1016/j.burns.2015.01.007. Epub 2015 Feb 21. Burns. 2015. PMID: 25716758 Review.
Cited by
-
Pediatric Thermal Burns and Treatment: A Review of Progress and Future Prospects.Medicines (Basel). 2017 Dec 11;4(4):91. doi: 10.3390/medicines4040091. Medicines (Basel). 2017. PMID: 29232903 Free PMC article. Review.
-
New Innovations for Deep Partial-Thickness Burn Treatment with ACell MatriStem Matrix.Adv Wound Care (New Rochelle). 2016 Dec 1;5(12):546-552. doi: 10.1089/wound.2015.0681. Adv Wound Care (New Rochelle). 2016. PMID: 28078188 Free PMC article.
-
Holistic Approach of Swiss Fetal Progenitor Cell Banking: Optimizing Safe and Sustainable Substrates for Regenerative Medicine and Biotechnology.Front Bioeng Biotechnol. 2020 Oct 23;8:557758. doi: 10.3389/fbioe.2020.557758. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 33195124 Free PMC article.
-
Effectiveness of Biobrane for treatment of partial-thickness burns in children.J Pediatr Surg. 2011 Sep;46(9):1759-63. doi: 10.1016/j.jpedsurg.2011.03.070. J Pediatr Surg. 2011. PMID: 21929986 Free PMC article.
-
Cutaneous Cell Therapy Manufacturing Timeframe Rationalization: Allogeneic Off-the-Freezer Fibroblasts for Dermo-Epidermal Combined Preparations (DE-FE002-SK2) in Burn Care.Pharmaceutics. 2023 Sep 16;15(9):2334. doi: 10.3390/pharmaceutics15092334. Pharmaceutics. 2023. PMID: 37765300 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical